/ALNAQ
ALNAQ Stock - Allena Pharmaceuticals, Inc.
Healthcare|BiotechnologyOTC
$0.00-99.00%
$0.00 (-99.00%) • Dec 11
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ALNAQ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.00 – $0.00
TARGET (TP)$0.00
STOP LOSS$0.00
RISK/REWARD1:-1.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-14.54
52W High$0.02
52W Low$0.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-32,335,000 | $-31,986,000 | $-46,920,000 | $-35,593,000 | $-20,950,000 |
| Net Income | $-33,355,000 | $-32,845,000 | $-47,339,000 | $-35,648,000 | $-21,650,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.03 | $-1.01 | $-2.13 | $-1.72 | $-4.79 |
Company Overview
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ALNAQBeat Rate
53%
Last 15 quarters
Avg Surprise
+1.4%
EPS vs Estimate
Beats / Misses
8/6
1 met exactly
Latest EPS
$-0.08
Q3 2022
EPS Surprise History
Q4 20
-4.8%
$-0.22vs$-0.21
Q1 21
-26.3%
$-0.24vs$-0.19
Q2 21
+8.7%
$-0.21vs$-0.23
Q3 21
-14.3%
$-0.24vs$-0.21
Q4 21
+5.6%
$-0.17vs$-0.18
Q1 22
+31.3%
$-0.11vs$-0.16
Q2 22
+7.1%
$-0.13vs$-0.14
Q3 22
-14.3%
$-0.08vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2023 | Nov 13, 2023 | — | — | — | — |
Q3 2023 | Sep 22, 2023 | — | — | — | — |
Q2 2023 | Jun 28, 2023 | — | — | — | — |
Q1 2023 | Feb 24, 2023 | — | — | — | — |
Q4 2022 | Dec 16, 2022 | $-0.05 | — | — | — |
Q3 2022 | Aug 15, 2022 | $-0.07 | $-0.08 | -14.3% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-0.14 | $-0.13 | +7.1% | ✓ BEAT |
Q1 2022 | Mar 31, 2022 | $-0.16 | $-0.11 | +31.3% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.18 | $-0.17 | +5.6% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-0.21 | $-0.24 | -14.3% | ✗ MISS |
Q2 2021 | May 11, 2021 | $-0.23 | $-0.21 | +8.7% | ✓ BEAT |
Q1 2021 | Mar 9, 2021 | $-0.19 | $-0.24 | -26.3% | ✗ MISS |
Q4 2020 | Nov 9, 2020 | $-0.21 | $-0.22 | -4.8% | ✗ MISS |
Q3 2020 | Aug 5, 2020 | $-0.27 | $-0.26 | +3.7% | ✓ BEAT |
Q2 2020 | May 13, 2020 | $-0.45 | $-0.31 | +31.1% | ✓ BEAT |
Q1 2020 | Mar 16, 2020 | $-0.53 | $-0.47 | +11.3% | ✓ BEAT |
Q4 2019 | Nov 13, 2019 | $-0.49 | $-0.57 | -16.3% | ✗ MISS |
Q3 2019 | Aug 7, 2019 | $-0.54 | $-0.54 | 0.0% | = MET |
Q2 2019 | May 8, 2019 | $-0.49 | $-0.55 | -12.2% | ✗ MISS |
Q1 2019 | Mar 7, 2019 | $-0.51 | $-0.46 | +9.8% | ✓ BEAT |
Latest News
Loading news...
Frequently Asked Questions about ALNAQ
What is ALNAQ's current stock price?
Allena Pharmaceuticals, Inc. (ALNAQ) is currently trading at $0.00 per share. The stock has moved -99.00% today.
What is the analyst price target for ALNAQ?
No analyst price targets are currently available for this stock.
What sector is Allena Pharmaceuticals, Inc. in?
Allena Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.
What is ALNAQ's market cap?
Allena Pharmaceuticals, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does ALNAQ pay dividends?
No, Allena Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBUGVF
Primo Nutraceuticals Inc.
$0.00
Mkt Cap: $0.0B
GRYN
Green Hygienics Holdings Inc.
$0.00
Mkt Cap: $0.0B
IMVIQ
IMV Inc.
$0.00
Mkt Cap: $0.0B
INDR
Indie Ranch Media, Inc.
$0.00
Mkt Cap: $0.0B
LHRP
LifeHOUSE Holdings, LLC
$0.00
Mkt Cap: $0.0B
PECN
Photoelectron Corp.
$0.00
Mkt Cap: $0.0B
QMED
QMed, Inc.
$0.00
Mkt Cap: $0.0B
RGBOQ
ReGen Biologics Inc.
$0.00
Mkt Cap: $0.0B
TAISF
Taisho Pharmaceutical Holdings Co., Ltd.
$59.00
Mkt Cap: $0.0B
TGVN
TGC Ventures International, Inc.
$0.00
Mkt Cap: $0.0B
Explore stocks similar to ALNAQ for comparison